Aptose Biosciences Inc  

(Public, NASDAQ:APTO)   Watch this stock  
Find more results for OTC:LRUSF
-0.20 (-3.13%)
Apr 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.75 - 6.47
52 week 4.01 - 8.80
Open 6.47
Vol / Avg. 0.00/31,449.00
Mkt cap 74.41M
P/E     -
Div/yield     -
EPS -1.34
Shares 11.77M
Beta 1.09
Inst. own 35%
Mar 24, 2015
Aptose Biosciences Inc at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 10, 2015
Aptose Biosciences Inc at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -42.00% -
Return on average equity -44.86% -
Employees 19 -
CDP Score - -


2 Meridian Rd
+1-416-7981200 (Phone)
+1-416-7982200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aptose Biosciences Inc is a clinical-stage biotechnology company. The Company is engaged in discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company�s drugs include APTO-253, IL-17E and APTO-500. APTO-253 is a small molecule with potent anti-tumor activity in cancer cells via tumor suppressor induction leading to cell cycle inhibition and programmed cell death. The Company discovered IL-17E, which has potent anticancer properties against a range of solid tumors in vivo, including human melanoma, pancreatic, colon, lung, ovarian and breast tumor models. APTO-500 program focuses on discovering and developing potent small molecule inhibitors of maternal embryonic leucine zipper kinase (MELK).

Officers and directors

William G. Rice Ph.D. Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Gregory K. Chow Chief Financial Officer, Senior Vice President
Bio & Compensation  - Reuters
Elizabeth Williams Finance Director, IR Contact Officer
Bio & Compensation  - Reuters
Avanish Vellanki Senior Vice President, Chief Business Officer
Bio & Compensation  - Reuters
Stephen B. Howell M.D. Chief Medical Officer
Age: 69
Bio & Compensation  - Reuters
Erich M. Platzer M.D., Ph.D. Director
Bio & Compensation  - Reuters
Denis R. Burger Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Bradley Thompson Independent Director
Bio & Compensation  - Reuters
Mark D. Vincent M.D. Independent Director
Bio & Compensation  - Reuters
Warren Whitehead Independent Director
Bio & Compensation  - Reuters